Physician profile
Wei Wang
NPI 1902813876
$72,680.04
in general payments reported to CMS, 2019-2025
24 companies · $6,193 in 2025
The $6,193 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,724 · 2020: $8,572 · 2021: $11K · 2022: $9,479 · 2023: $18K · 2024: $11K · 2025: $6,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $5,556 · Travel and Lodging: $888 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,850.00 |
| Food and Beverage | $5,556.05 |
| Travel and Lodging | $887.66 |
| Education | $251.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46,768.14 | 2021-2025 | Vraylar |
| Allergan, INC. | $16,074.10 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $2,252.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,954.09 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $1,884.22 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,744.83 | 2020-2025 | Caplyta |
| Lundbeck LLC | $546.58 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neos Therapeutics, LP | $387.53 | 2019-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $214.17 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $121.98 | 2019-2022 | |
| Bausch Health US, LLC | $118.22 | 2019-2022 | |
| Brainsway USA INC | $96.24 | 2020 | |
| Indivior INC. | $93.55 | 2019 | |
| Vanda Pharmaceuticals INC. | $63.24 | 2024-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $55.54 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.60 | 2024-2025 | Cobenfy |
| Azurity Pharmaceuticals, INC. | $45.01 | 2023 | Horizant |
| Neurocrine Biosciences, INC. | $42.65 | 2019 | |
| Supernus Pharmaceuticals, INC. | $42.48 | 2024 | Qelbree |
| Sanofi Pasteur INC. | $38.85 | 2023-2025 | |
| Owp Pharmaceuticals, INC. | $27.52 | 2022-2024 | Subvenite |
| Ironshore Pharmaceuticals INC. | $26.48 | 2019 | |
| Boston Scientific Corporation | $18.12 | 2025 | Exalt Model D |
| Aytu Biopharma, INC. | $16.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.